Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
A phase 3 trial testing AAA817 in prostate cancer, now recruiting.
Overview
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC is a phase 3 interventional study registered as NCT06855277, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: A Phase III, Open-label, Multi-centre, Randomised Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer. Planned enrolment is 940 participants (estimated). The study started in 2025-07-01 and primary completion is expected in 2028-09-29. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares AAA817, Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.